Thought Archive

RFK’s Vaccine War Reaches the Pharmacies

29 Aug 2025

RFK’s Vaccine War Reaches the Pharmacies

RFK’s Vaccine War Reaches the Pharmacies

Hook

When America’s largest pharmacy chain pulls the brakes on COVID shots, you know something fundamental has shifted.

Context

CVS confirmed it will hold off on offering COVID-19 vaccines in 16 states, citing the need for formal recommendations from the CDC’s newly restructured advisory panel.
This comes just days after the FDA restricted vaccine access to older adults and high-risk patients — and months after RFK Jr. removed healthy kids and pregnant women from CDC guidance altogether.

For ordinary Americans, the message is clear: the vaccine landscape you thought you knew has been dismantled.

My Take

This is no longer a quiet bureaucratic shuffle. Pharmacies are on pause. Medical groups are in open revolt. The CDC’s advisory system has been gutted and replaced with voices far more skeptical of vaccines.

CVS isn’t acting out of caution alone — it’s acting out of necessity. In the fog of RFK’s policy war, even corporate giants are waiting for signals before taking a step.

The irony? Pharmacies like CVS once expanded vaccine access by sheer convenience. Now they’re symbols of uncertainty.

Implications

  • Access choke point: If CVS is pausing, other chains may follow, leaving seniors and high-risk patients with fewer options.
  • Medical pushback: Groups like the AAP and ACOG are openly recommending vaccines against federal policy, deepening the divide between public health institutions and political leadership.
  • Insurance cliff: Coverage may hold through this fall — but beyond that, insurers will look to CDC guidance, and that guidance is anyone’s guess.
  • September showdown: All eyes are on the Sept. 18–19 ACIP meeting, which could cement the new vaccine reality or fracture it further.

Further Reading

Closing

CVS’s pause isn’t just about 16 states. It’s a snapshot of a nation caught in the middle of a high-stakes gamble: RFK’s crusade against vaccines has moved from talking points to the pharmacy counter.

The next move belongs to the CDC’s reshaped advisory panel — but the cost of hesitation is already rippling across the country.